JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Compugen Ltd

Uždarymo kaina

1.52 -0.65

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.5

Max

1.52

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.1M

-7.2M

Pardavimai

813K

2.3M

P/E

Sektoriaus vid.

60.333

38.156

Pelno marža

-314.405

Darbuotojai

74

EBITDA

-912K

-8.4M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+357.52% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-545M

141M

Ankstesnė atidarymo kaina

2.17

Ankstesnė uždarymo kaina

1.52

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-25 17:53; UTC

Pagrindinės rinkos jėgos

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

2025-07-25 15:58; UTC

Uždarbis
Pagrindinės rinkos jėgos

Aon Shares Rise After 2Q Earnings Beat

2025-07-25 15:08; UTC

Pagrindinės rinkos jėgos

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

2025-07-25 21:40; UTC

Rinkos pokalbiai

Starbucks' Spending Hikes Are Misdirected -- Market Talk

2025-07-25 21:23; UTC

Rinkos pokalbiai

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

2025-07-25 20:40; UTC

Uždarbis

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

2025-07-25 20:10; UTC

Uždarbis

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 19:56; UTC

Uždarbis

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

2025-07-25 19:14; UTC

Rinkos pokalbiai

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

2025-07-25 19:10; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

2025-07-25 19:01; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 18:45; UTC

Rinkos pokalbiai

Gold Ends Down Week on Lower Note -- Market Talk

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

Sale Could Fetch Around $1B, Sources Say -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

LVMH in Talks to Sell Marc Jacobs -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

2025-07-25 17:38; UTC

Pagrindinės rinkos jėgos

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

2025-07-25 17:26; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Extends Decline -- Market Talk

2025-07-25 17:13; UTC

Uždarbis

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

2025-07-25 16:46; UTC

Uždarbis

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

2025-07-25 16:45; UTC

Uždarbis

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

2025-07-25 16:27; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-25 16:02; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

2025-07-25 15:34; UTC

Uždarbis

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

2025-07-25 15:06; UTC

Rinkos pokalbiai

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

2025-07-25 15:05; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

2025-07-25 14:45; UTC

Rinkos pokalbiai

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

2025-07-25 14:44; UTC

Rinkos pokalbiai

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

2025-07-25 14:36; UTC

Rinkos pokalbiai
Uždarbis

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

357.52% į viršų

12 mėnesių prognozė

Vidutinis 7 USD  357.52%

Aukščiausias 10 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.25 / 1.48Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.